MondayNightIBD
Evolving Treatment Targets and Monitoring Strategies in Crohn's Disease
October 14, 2024 ~ Jami Kinnucan, MD
***Post-Survey & Application for CME Credit***

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.
1.What are your specialty & credentials?(Required.)
2.What is your community of practice?
3.According to STRIDE-II, which of the following is considered an intermediate treatment target for IBD?(Required.)
4.A 32-year-old woman with newly diagnosed Crohn’s ileocolitis is started on ustekinumab and achieves endoscopic healing at year 1 with some pseudopolyps in right colon and a short non-obstructing fibrotic stenosis at the ileocaecal valve.

Which of following is a long term T2T for her?
(Required.)
EVALUATION FORM
5.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease
6.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
7.Overall, was this activity fair, balanced and free from commercial bias?
8.If no, please explain:
9.Of the patients with IBD you will see in the next month, about how many will benefit from the information you learned today?
10.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
11.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
12.For purposes of certification, you must complete the following information.
*Please note that we will not forward or sell your contact information.*
(Required.)
13.I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Evolving Treatment Targets & Monitoring Strategies in Crohn's Disease" and claim 0.5 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com
Privacy & Cookie Notice